Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1997 5
1998 10
1999 20
2000 9
2001 6
2002 5
2003 7
2004 8
2005 12
2006 10
2007 17
2008 18
2009 17
2010 19
2011 30
2012 37
2013 30
2014 34
2015 38
2016 39
2017 45
2018 47
2019 44
2020 53
2021 54
2022 33
2023 29
2024 34
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

634 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Molecular Classification of Lung Cancer.
Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Rodriguez-Canales J, et al. Among authors: wistuba ii. Cancer Treat Res. 2016;170:25-46. doi: 10.1007/978-3-319-40389-2_2. Cancer Treat Res. 2016. PMID: 27535388 Review.
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. Doroshow DB, et al. Among authors: wistuba ii. Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. doi: 10.1038/s41571-021-00473-5. Epub 2021 Feb 12. Nat Rev Clin Oncol. 2021. PMID: 33580222 Review.
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Gay CM, et al. Among authors: wistuba ii. Cancer Cell. 2021 Mar 8;39(3):346-360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21. Cancer Cell. 2021. PMID: 33482121 Free PMC article.
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Panda A, Fang J, Skoulidis F, Wistuba II, Verma S, Merghoub T, Wolchok JD, Wong KK, DeBerardinis RJ, Minna JD, Vokes NI, Meador CB, Gainor JF, Wang L, Reuben A, Heymach JV. Qian Y, et al. Among authors: wistuba ii. Cancer Cell. 2023 Jul 10;41(7):1363-1380.e7. doi: 10.1016/j.ccell.2023.05.015. Epub 2023 Jun 15. Cancer Cell. 2023. PMID: 37327788 Free PMC article.
Lung Cancer Biomarkers.
Villalobos P, Wistuba II. Villalobos P, et al. Among authors: wistuba ii. Hematol Oncol Clin North Am. 2017 Feb;31(1):13-29. doi: 10.1016/j.hoc.2016.08.006. Hematol Oncol Clin North Am. 2017. PMID: 27912828 Free PMC article. Review.
An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. Han G, et al. Among authors: wistuba ii. Nature. 2024 Mar;627(8004):656-663. doi: 10.1038/s41586-024-07113-9. Epub 2024 Feb 28. Nature. 2024. PMID: 38418883 Free PMC article.
Pathology and Classification of SCLC.
Raso MG, Bota-Rabassedas N, Wistuba II. Raso MG, et al. Among authors: wistuba ii. Cancers (Basel). 2021 Feb 16;13(4):820. doi: 10.3390/cancers13040820. Cancers (Basel). 2021. PMID: 33669241 Free PMC article. Review.
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP; LCMC study investigators. Chaft JE, et al. Among authors: wistuba ii. Nat Med. 2022 Oct;28(10):2155-2161. doi: 10.1038/s41591-022-01962-5. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097216 Free PMC article. Clinical Trial.
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Chang JY, et al. Among authors: wistuba ii. Lancet. 2023 Sep 9;402(10405):871-881. doi: 10.1016/S0140-6736(23)01384-3. Epub 2023 Jul 18. Lancet. 2023. PMID: 37478883 Free PMC article. Clinical Trial.
634 results